Anaptysbio Inc(ANAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ANAB Anaptysbio Inc

未开盘 02-24 16:00:00 EST

55.41

+1.12

+2.06%

盘后52.78

-2.63-4.75%

19:37 EST

最高57.74	最低54.91	成交量23.60万
今开54.91	昨收54.29	日振幅5.21%
总市值15.34亿	流通市值7.90亿	总股本2,769万
成交额1,322万	换手率1.66%	流通股本1,425万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ANAB","market":"US","secType":"STK","nameCN":"Anaptysbio Inc","latestPrice":55.41,"timestamp":1771966800000,"preClose":54.29,"halted":0,"volume":235957,"hourTrading":{"tag":"盘后","latestPrice":52.779,"preClose":55.41,"latestTime":"19:37 EST","volume":13817,"amount":764429.1663,"timestamp":1771979840095,"change":-2.631,"changeRate":-0.047482,"amplitude":0.047482},"delay":0,"changeRate":0.02062995026708413,"floatShares":14248500,"shares":27688470,"eps":-2.875661,"marketStatus":"未开盘","change":1.12,"latestTime":"02-24 16:00:00 EST","open":54.91,"high":57.74,"low":54.91,"amount":13218597.591798,"amplitude":0.052127,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.875661,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772010000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1485406800000,"exchange":"NASDAQ","adjPreClose":54.29,"postHourTrading":{"tag":"盘后","latestPrice":52.779,"preClose":55.41,"latestTime":"19:37 EST","volume":13817,"amount":764429.1663,"timestamp":1771979840095,"change":-2.631,"changeRate":-0.047482,"amplitude":0.047482},"volumeRatio":0.637109,"impliedVol":0.5848,"impliedVolPercentile":0.3307},"requestUrl":"/m/hq/s/ANAB","defaultTab":"news","newsList":[{"id":"1111505663","title":"Anaptysbio提交动议 请求法院驳回Tesaro关于预期违约的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1111505663","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111505663?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:01","pubTimestamp":1767913272,"startTime":"0","endTime":"0","summary":"在针对葛兰素史克（GSK）旗下子公司Tesaro的持续诉讼中，Anaptysbio公司（ANAB）已正式向法院提交动议，要求驳回Tesaro提出的预期违约合同指控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"gpt_icon":0},{"id":"1124874010","title":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1124874010","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124874010?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:03","pubTimestamp":1765800198,"startTime":"0","endTime":"0","summary":"万达生物制药：优先审查将确立6个月审查周期，Imsidolimab有望于2026年中期获得FDA批准用于GPP治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","VNDA","BK4139"],"gpt_icon":0},{"id":"1127045654","title":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1127045654","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127045654?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:02","pubTimestamp":1765800154,"startTime":"0","endTime":"0","summary":"万达生物制药提交生物制剂许可证申请给FDA，申请用于治疗广义脓疱型银屑病的Imsidolimab","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB","VNDA"],"gpt_icon":0},{"id":"1146022492","title":"Anaptysbio Inc - 11月26日，公司对Tesaro违反协议的投诉已公开提交 - SEC申报","url":"https://stock-news.laohu8.com/highlight/detail?id=1146022492","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146022492?lang=zh_cn&edition=full","pubTime":"2025-11-27 05:05","pubTimestamp":1764191110,"startTime":"0","endTime":"0","summary":"Anaptysbio Inc - 11月26日，公司对Tesaro违反协议的投诉已公开提交 - SEC申报","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"gpt_icon":0},{"id":"1164707323","title":"葛兰素史克在Anaptysbio指控Tesaro未履行2014年3月签署的许可协议某些要求后启动诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1164707323","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164707323?lang=zh_cn&edition=full","pubTime":"2025-11-21 07:22","pubTimestamp":1763680923,"startTime":"0","endTime":"0","summary":"葛兰素史克在Anaptysbio指控Tesaro未履行2014年3月签署的许可协议某些要求后启动诉讼","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1645745479.HKD","GSK.UK","LU0321505868.SGD","LU0225771236.USD","LU1098665638.USD","LU1228905037.USD","LU1309081286.SGD","LU1400636657.SGD","IE0034235071.USD","BK5011","LU1015430645.USD","LU1487256676.USD","ANAB","LU0058720904.USD","LU1302929846.USD","LU0203347892.USD","LU0109981661.USD","LU1481600234.SGD","LU1035777561.USD","LU0289739699.SGD","LU1202635105.USD","LU0306807586.USD","LU1481599808.USD","LU0211331839.USD","LU1670756490.USD","LU0971552830.HKD","LU0321505439.SGD","LU0575583348.USD","LU1400636491.USD","LU0545562505.USD","IE00BWDBJ516.SGD","LU0225284248.USD","LU0985481810.HKD","LU1064927863.SGD","LU0971552673.USD","BK4139","LU1228905540.USD","LU1400636574.HKD","LU0161305163.EUR","LU0203345920.USD","LU1046248800.SGD","IE00B3T34201.USD","IE00BQJZX424.USD","LU0306806265.USD"],"gpt_icon":0},{"id":"1105594410","title":"葛兰素史克：违约使特萨罗有权终止当前许可协议，并获得对Dostarlimab的永久且不可撤销的许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1105594410","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105594410?lang=zh_cn&edition=full","pubTime":"2025-11-21 07:18","pubTimestamp":1763680702,"startTime":"0","endTime":"0","summary":"葛兰素史克：违约使特萨罗有权终止当前许可协议，并获得对Dostarlimab的永久且不可撤销的许可","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1400636574.HKD","LU0575583348.USD","LU1228905540.USD","LU1302929846.USD","LU0225771236.USD","LU1064927863.SGD","LU1035777561.USD","LU0203345920.USD","ANAB","LU1228905037.USD","LU0985481810.HKD","LU0971552830.HKD","LU0109981661.USD","LU0306806265.USD","BK5011","LU1098665638.USD","LU0058720904.USD","LU1202635105.USD","LU1481600234.SGD","IE00BWDBJ516.SGD","IE0034235071.USD","LU1309081286.SGD","IE00B3T34201.USD","LU1487256676.USD","LU0971552673.USD","LU0203347892.USD","LU1481599808.USD","LU1015430645.USD","LU1400636491.USD","LU0161305163.EUR","LU0211331839.USD","LU0306807586.USD","LU1645745479.HKD","LU1670756490.USD","LU1046248800.SGD","GSK.UK","BK4139","LU0225284248.USD","LU0321505439.SGD","LU1400636657.SGD","IE00BQJZX424.USD","LU0321505868.SGD","LU0545562505.USD"],"gpt_icon":0},{"id":"1189350810","title":"葛兰素史克：Anaptysbio最近的行为严重违反了与Tesaro关于肿瘤治疗Jemperli的现有许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1189350810","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189350810?lang=zh_cn&edition=full","pubTime":"2025-11-21 07:17","pubTimestamp":1763680645,"startTime":"0","endTime":"0","summary":"葛兰素史克：Anaptysbio最近的行为严重违反了与Tesaro关于肿瘤治疗Jemperli的现有许可协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0161305163.EUR","LU0575583348.USD","LU1228905540.USD","GSK.UK","LU0971552673.USD","LU0211331839.USD","LU1302929846.USD","LU0321505868.SGD","LU1309081286.SGD","IE00BQJZX424.USD","IE00B3T34201.USD","LU0225771236.USD","LU0058720904.USD","LU1400636657.SGD","LU1487256676.USD","LU0321505439.SGD","LU0225284248.USD","LU1202635105.USD","IE00BWDBJ516.SGD","LU0985481810.HKD","BK5011","LU1481600234.SGD","ANAB","LU1064927863.SGD","LU0306807586.USD","LU1400636491.USD","IE0034235071.USD","LU0203347892.USD","LU0545562505.USD","LU1481599808.USD","LU1046248800.SGD","LU0289739699.SGD","LU0203345920.USD","LU1400636574.HKD","LU0971552830.HKD","LU1015430645.USD","LU1228905037.USD","LU1098665638.USD","LU1670756490.USD","LU1035777561.USD","LU0109981661.USD","LU1645745479.HKD","LU0306806265.USD"],"gpt_icon":0},{"id":"2585515990","title":"Anaptysbio, Inc.盘中异动 急速上涨5.28%报38.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585515990","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585515990?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:50","pubTimestamp":1763650225,"startTime":"0","endTime":"0","summary":"北京时间2025年11月20日22时50分，Anaptysbio, Inc.股票出现异动，股价急速上涨5.28%。截至发稿，该股报38.97美元/股，成交量2.351万股，换手率0.08%，振幅3.89%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为1.51%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Annexon, Inc.、Design Therapeutics, Inc.涨幅较大，Psyence Biomedical Ltd.、Clearmind Medicine Inc.、Kazia Therapeutics Limited较为活跃，换手率分别为954.91%、37.38%、14.49%，振幅较大的相关个股有Immutep Ltd、Biorestorative Therapies, Inc.、康乃德生物，振幅分别为102.05%、21.68%、20.32%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120225026a706fe38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANAB","BK4132","AD","RA","BK4139"],"gpt_icon":0},{"id":"1132374256","title":"异动解读 | Anaptysbio新药试验失败，股价盘中暴跌19.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132374256","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132374256?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:57","pubTimestamp":1762786626,"startTime":"0","endTime":"0","summary":"生物制药公司Anaptysbio Inc今日盘中股价暴跌19.29%，引发市场广泛关注。导致股价大跌的主要原因是公司于今日早间发布了一则重要公告。Anaptysbio宣布，其重点研发的药物Rosnilimab在针对中重度溃疡性结肠炎的第二阶段临床试验中，未能达到主要或次要终点。这一消息对Anaptysbio的未来发展可能产生深远影响。Rosnilimab是公司重要的在研药物之一，其在溃疡性结肠炎治疗领域的失利，不仅可能延缓该药物的开发进程，还可能影响公司在自身免疫疾病治疗领域的整体布局。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ANAB"],"gpt_icon":0},{"id":"1120423178","title":"Anaptys发布消息：Rosnilimab的第二阶段试验在中重度溃疡性结肠炎中未达到主要或次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1120423178","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120423178?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:01","pubTimestamp":1762783281,"startTime":"0","endTime":"0","summary":"Anaptys发布消息：Rosnilimab的第二阶段试验在中重度溃疡性结肠炎中未达到主要或次要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"gpt_icon":0},{"id":"1121946184","title":"Anaptysbio Inc 公布 Rosnilimab 在类风湿关节炎的最新积极 2B 期临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1121946184","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121946184?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:15","pubTimestamp":1761743709,"startTime":"0","endTime":"0","summary":"Anaptysbio Inc 公布 Rosnilimab 在类风湿关节炎的最新积极 2B 期临床试验结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"gpt_icon":0},{"id":"1165748493","title":"Anaptys宣布将在即将举行的ACR Convergence 2025大会上口头报告Rosnilimab治疗类风湿关节炎的完整2B期试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1165748493","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165748493?lang=zh_cn&edition=full","pubTime":"2025-10-13 21:16","pubTimestamp":1760361385,"startTime":"0","endTime":"0","summary":"Anaptys宣布将在即将举行的ACR Convergence 2025大会上口头报告Rosnilimab治疗类风湿关节炎的完整2B期试验数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ANAB"],"gpt_icon":0},{"id":"1125225113","title":"Anaptysbio Inc：完成相关事项后 生物制药公司将获得充足资金支持至少两年运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1125225113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125225113?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:08","pubTimestamp":1759176510,"startTime":"0","endTime":"0","summary":"Anaptysbio Inc表示，在完成相关事项后，这家生物制药公司将正式启动运营，并拥有充足的资本金来支持公司至少两年的业务运营。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139"],"gpt_icon":0},{"id":"1161751831","title":"AnaptysBio Inc：交易完成后 版税管理公司将管理包括Jemperli和Imsidolimab在内的版税收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1161751831","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161751831?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:08","pubTimestamp":1759176495,"startTime":"0","endTime":"0","summary":"AnaptysBio Inc宣布，在相关交易完成后，版税管理公司将负责管理其版税收入，其中包括Jemperli和Imsidolimab等产品的版税。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139"],"gpt_icon":0},{"id":"1123519263","title":"Anaptysbio Inc宣布计划在2026年底前将生物制药业务与大额特许权使用费资产分离","url":"https://stock-news.laohu8.com/highlight/detail?id=1123519263","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123519263?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:06","pubTimestamp":1759176373,"startTime":"0","endTime":"0","summary":"Anaptysbio Inc宣布计划在2026年底前将生物制药业务与大额特许权使用费资产分离。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139"],"gpt_icon":0},{"id":"2570035316","title":"Anaptysbio, Inc.盘中异动 股价大涨5.54%报22.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570035316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570035316?lang=zh_cn&edition=full","pubTime":"2025-09-24 21:43","pubTimestamp":1758721408,"startTime":"0","endTime":"0","summary":"北京时间2025年09月24日21时43分，Anaptysbio, Inc.股票出现波动，股价急速拉升5.54%。截至发稿，该股报22.11美元/股，成交量5.2759万股，换手率0.19%，振幅4.58%。Anaptysbio, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Uniqure N.V.、Osr Holdings Inc C/Wts 09/02/2028 、Cyclerion Therapeutics, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Jaguar Health, Inc.、Uniqure N.V.较为活跃，换手率分别为347.15%、35.38%、28.21%，振幅较大的相关个股有Uniqure N.V.、Pharmacyte  Biotech, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为35.58%、28.69%、20.87%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214329a69b797d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214329a69b797d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4132","BK4139","ANAB","RA","AD"],"gpt_icon":0},{"id":"2568285278","title":"Anaptysbio, Inc.盘中异动 快速拉升5.15%报20.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568285278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568285278?lang=zh_cn&edition=full","pubTime":"2025-09-19 02:27","pubTimestamp":1758220046,"startTime":"0","endTime":"0","summary":"北京时间2025年09月19日02时27分，Anaptysbio, Inc.股票出现异动，股价快速拉升5.15%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。消息层面，截至02时27分，《韦德布什维持AnaptysBio买入评级，维持目标价45美元》资讯为影响Anaptysbio, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509190227279536fbfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509190227279536fbfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RA","AD","BK4132","ANAB"],"gpt_icon":0},{"id":"2568480974","title":"Anaptysbio, Inc.盘中异动 早盘股价大跌5.31%报19.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568480974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568480974?lang=zh_cn&edition=full","pubTime":"2025-09-16 21:39","pubTimestamp":1758029970,"startTime":"0","endTime":"0","summary":"北京时间2025年09月16日21时39分，Anaptysbio, Inc.股票出现波动，股价急速下跌5.31%。截至发稿，该股报19.09美元/股，成交量8.8507万股，换手率0.32%，振幅5.83%。Anaptysbio, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Aptevo Therapeutics Inc.、Surrozen Inc C/Wts 01/08/2031 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Aptevo Therapeutics Inc.、Silo Pharma, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为1847.59%、102.23%、74.24%，振幅较大的相关个股有Aptevo Therapeutics Inc.、Adaptimmune Therapeutics Plc、冠科美博，振幅分别为40.97%、31.68%、19.16%。Anaptysbio, Inc.公司简介：AnaptysBio Inc是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916213930a4c9ac98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916213930a4c9ac98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RA","ANAB","AD","BK4139","BK4132"],"gpt_icon":0},{"id":"2518540447","title":"Anaptysbio, Inc.2024财年实现净利润-1.45亿美元，同比增加11.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518540447","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518540447?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449634,"startTime":"0","endTime":"0","summary":"3月9日，Anaptysbio, Inc.公布财报，公告显示公司2024财年净利润为-1.45亿美元，同比增加11.59%；其中营业收入为91.28百万美元，同比增加431.93%，每股基本收益为-5.12美元。从资产负债表来看，Anaptysbio, Inc.总负债4.13亿美元，其中短期债务1.93百万美元，资产负债比为1.18，流动比率为0.10。机构评级：截至2025年3月9日，当前有11家机构对Anaptysbio, Inc.目标价做出预测，其中目标均价为37.64美元，其中最低目标价为18.00美元，最高目标价为57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000109abef972f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000109abef972f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ANAB"],"gpt_icon":0},{"id":"2517198212","title":"Anaptysbio, Inc.盘中异动 大幅跳水5.07%报15.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517198212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517198212?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:12","pubTimestamp":1741281178,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时12分，Anaptysbio, Inc.股票出现波动，股价大幅下跌5.07%。截至发稿，该股报15.90美元/股，成交量14.7412万股，换手率0.48%，振幅4.72%。Anaptysbio, Inc.股票所在的生物技术行业中，整体跌幅为0.79%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com涨幅较大，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为3191.22%、2706.07%、219.82%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.，振幅分别为125.28%、105.20%、71.44%。Anaptysbio, Inc.公司简介：AnaptysBio Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307011259a262b72b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307011259a262b72b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ANAB","RA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.anaptysbio.com","stockEarnings":[{"period":"1week","weight":0.0228},{"period":"1month","weight":0.142},{"period":"3month","weight":0.3082},{"period":"6month","weight":1.6613},{"period":"1year","weight":1.9204},{"period":"ytd","weight":0.1198}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AnaptysBio, Inc.在特拉华成立于2005年11月。该公司是一家临床阶段的生物技术公司，专注于提供创新的免疫学疗法。该公司正在开发免疫细胞调节抗体，包括两种处于临床阶段开发阶段的全资拥有的检查点激动剂，用于自身免疫和炎症性疾病：rosnilimab，公司PD-1激动剂用于治疗中度至重度类风湿性关节炎（“RA”）的2b期试验和治疗中度至重度溃疡性结肠炎（“UC”）的2期试验；ANB032，公司BTLA激动剂，用于治疗中度至重度特应性皮炎（“AD”）的2b期试验。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.038027},{"month":2,"riseRate":0.8,"avgChangeRate":0.086881},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062379},{"month":4,"riseRate":0.444444,"avgChangeRate":0.025073},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.028144},{"month":6,"riseRate":0.555556,"avgChangeRate":0.006626},{"month":7,"riseRate":0.555556,"avgChangeRate":0.028667},{"month":8,"riseRate":0.555556,"avgChangeRate":0.01626},{"month":9,"riseRate":0.555556,"avgChangeRate":0.060315},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200667},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.043934},{"month":12,"riseRate":0.666667,"avgChangeRate":0.055221}],"exchange":"NASDAQ","name":"Anaptysbio Inc","nameEN":"Anaptysbio Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Anaptysbio Inc(ANAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Anaptysbio Inc(ANAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Anaptysbio Inc,ANAB,Anaptysbio Inc股票,Anaptysbio Inc股票老虎,Anaptysbio Inc股票老虎国际,Anaptysbio Inc行情,Anaptysbio Inc股票行情,Anaptysbio Inc股价,Anaptysbio Inc股市,Anaptysbio Inc股票价格,Anaptysbio Inc股票交易,Anaptysbio Inc股票购买,Anaptysbio Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Anaptysbio Inc(ANAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Anaptysbio Inc(ANAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}